Myeloma Canada Aurelia Initiative: Funding Myeloma Research
Myeloma Canada’s Aurelia Research Grants fund innovative, patient-centred research that targets the most pressing gaps in diagnosisThe process of identifying a disease by its signs and symptoms., treatment, and scientific understanding. We’re transforming commitment into impact — improving lives, extending survival, and accelerating progress toward a cure.
Research Priorities that Matter Most to the Community
We believe the best research starts by listening to those most affected. That’s why we asked people living with myeloma, their caregivers, and the healthcare professionals who support them to tell us what research they feel is most important. This national priority-setting process helped ensure that the research we fund truly reflects the needs and experiences of the Canadian myeloma community.
Together, they identified the top 10 research priorities, which now guide all our funding decisions. These priorities focus on the areas that can make the biggest difference in the lives of patients and their families.
These priorities include:
- Finding a cure
- Advancing immunotherapies
- Improving early diagnosis
- Personalizing treatment
- Reducing treatment side effectsProblems that occur due to drugs used for disease treatment. Common side effects of cancer treatment are fatigue, nausea, vomiting, decreased blood cell counts, hair loss, and mouth sores.
- Enhancing quality-of-life
- Addressing bone damage
- Managing drug resistanceThe result of cells' ability to resist the effects of a specific drug. and relapsed disease
- Supporting high-risk patients
- Improving access and equity across the healthcare system
Our Funding Model
Myeloma Canada funds important, life-changing research thanks to generous community fundraising, donations, and partnerships with organizations that share our goals.
To make sure every dollar goes to the most promising and meaningful projects, all research proposals go through a careful and fair review process. This process follows global best practices to ensure transparency and integrity.
Each application is reviewed by Myeloma Canada’s Independent Research Review Committee (IRRC), which includes healthcare professionals, scientists, and people personally affected by myeloma.
The IRRC looks at:
- How well the project addresses our top research priorities
- The strength and originality of the science
- Whether the project is realistic, likely to make a difference, and meaningfully includes patients
Progress Reporting: Transparency and Accountability
All funded researchers must submit interim and final progress reports to track milestones and ensure transparency for our community, donors, and partners.
Report highlights include:
- Summary of progress and findings
- Updates on patient/community involvement
- Knowledge-sharing efforts (e.g., publications or presentations)
- Future plans for continuation or additional funding
Aurelia Research Funding Strategy
Together, we’re shaping a brighter future for people impacted by myeloma through impactful, patient-focused research.